MXPA05010597A - Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi. - Google Patents

Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.

Info

Publication number
MXPA05010597A
MXPA05010597A MXPA05010597A MXPA05010597A MXPA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A
Authority
MX
Mexico
Prior art keywords
breast cancer
hydroxy tamoxifen
prevention
treatment
patients
Prior art date
Application number
MXPA05010597A
Other languages
English (en)
Inventor
Philippe Rouanet
Original Assignee
Lab Besins Internat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Besins Internat filed Critical Lab Besins Internat
Publication of MXPA05010597A publication Critical patent/MXPA05010597A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Abstract

La presente invencion proporciona metodos para tratar y prevenir el cancer de mama al administrar tamoxifen 4-hidroxi a un paciente. Tambien se proporciona composiciones farmaceuticas de tamoxifen 4-hidroxi adecuadas para la administracion percutanea. Cuando se administra percutaneamente a las mamas de un paciente, el tamoxifen 4-hidroxi se concentra localmente, y ejerce un efecto anti-estrogenico. En los pacientes con cancer de mama, este efecto reduce la proliferacion de tejido tumoral. En los pacientes en riesgo de desarrollar cancer de mama, el efecto anti-estrogenico previene la formacion de tumor de mama.
MXPA05010597A 2003-04-01 2003-12-15 Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi. MXPA05010597A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
MXPA05010597A true MXPA05010597A (es) 2006-03-09

Family

ID=33131847

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010597A MXPA05010597A (es) 2003-04-01 2003-12-15 Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.

Country Status (12)

Country Link
US (2) US7704516B2 (es)
EP (3) EP1952810B1 (es)
JP (1) JP5490346B2 (es)
AU (1) AU2003294973B2 (es)
CA (1) CA2519980C (es)
ES (3) ES2483896T3 (es)
HK (2) HK1086193A1 (es)
IL (1) IL170807A (es)
MX (1) MXPA05010597A (es)
NO (1) NO333805B1 (es)
NZ (1) NZ542499A (es)
WO (1) WO2004087123A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4938237B2 (ja) * 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
EP1572171B1 (en) * 2002-12-18 2009-04-22 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
EP1952810B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Treatment of breast cancer with 4-hydroxytamoxifen
WO2004110420A1 (en) * 2003-06-09 2004-12-23 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
ATE391499T1 (de) * 2004-03-22 2008-04-15 Besins Int Lab 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
WO2015175561A1 (en) 2014-05-12 2015-11-19 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
KR102178215B1 (ko) * 2014-08-27 2020-11-12 도요보 가부시키가이샤 저유전 접착제 조성물
WO2016094854A2 (en) * 2014-12-12 2016-06-16 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
JP7131773B2 (ja) * 2016-04-29 2022-09-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
US20210009865A1 (en) 2018-03-07 2021-01-14 Toagosei Co., Ltd. Adhesive composition, and adhesive layer-equipped layered product using same
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
DE3781546D1 (de) * 1987-04-21 1992-10-08 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-beta-dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (es) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
ES2156361T5 (es) * 1996-03-29 2012-12-26 Keyvest Gmbh Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
WO1999033451A2 (en) 1997-12-23 1999-07-08 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
ES2239057T3 (es) 1999-12-16 2005-09-16 Dermatrends, Inc. Agentes de liberacion de hidroxido utilizados como potenciadores de la permeacion cutanea.
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
ES2330188T3 (es) * 2001-12-07 2009-12-07 Besins Manufacturing Belgium Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones.
EP1572171B1 (en) * 2002-12-18 2009-04-22 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
JP4938237B2 (ja) * 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
EP1952810B1 (en) 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Treatment of breast cancer with 4-hydroxytamoxifen
WO2004110420A1 (en) * 2003-06-09 2004-12-23 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579857A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
NO20054526L (no) 2005-09-30
HK1119950A1 (en) 2009-03-20
EP1608353A1 (en) 2005-12-28
CA2519980A1 (en) 2004-10-14
WO2004087123A1 (en) 2004-10-14
AU2003294973A1 (en) 2004-10-25
NZ542499A (en) 2008-10-31
JP2006514967A (ja) 2006-05-18
ES2483896T3 (es) 2014-08-08
US20090186944A1 (en) 2009-07-23
US8475814B2 (en) 2013-07-02
ES2456957T3 (es) 2014-04-24
AU2003294973B2 (en) 2010-05-13
IL170807A (en) 2014-08-31
EP1952810A1 (en) 2008-08-06
US20050031695A1 (en) 2005-02-10
HK1086193A1 (en) 2006-09-15
JP5490346B2 (ja) 2014-05-14
EP1608353B1 (en) 2014-04-30
CA2519980C (en) 2012-04-10
EP1941871A1 (en) 2008-07-09
EP1941871B1 (en) 2014-01-08
ES2456958T3 (es) 2014-04-24
EP1952810B1 (en) 2014-01-08
US7704516B2 (en) 2010-04-27
NO333805B1 (no) 2013-09-16

Similar Documents

Publication Publication Date Title
MXPA05010597A (es) Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
RU2012148710A (ru) Органическое соединение для применения при лечении рака печени
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
HK1104968A1 (en) Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof
WO2002043720A3 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
BRPI0606774A2 (pt) método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2
US10758514B2 (en) Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
RU2011151854A (ru) Новые терапевтические способы применения инекальцитола
Ursino et al. Anaplastic thyroid cancer: a case report of a long term survival patient and review of literature data
EA201270298A1 (ru) Способ лечения злокачественной опухоли
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
NO20062904L (no) Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
WO2002094199A3 (en) METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD
Swapnil et al. Targeted Drug Delivery: A Backbone for Cancer Therapy
HK1096595A1 (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20140100174A1 (en) Treatment for Cancer
Michalopoulos et al. Gynecomastia induced by prostate-cancer treatment
Baghi et al. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck
Thorstad et al. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data
Burton Proton-Beam RT Effective Against Choroidal Melanoma
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
MX2023008155A (es) Regimenes de tratamiento con dosis fijas de tamibaroteno.
Karthika Oral Toxicities Due to Cancer Therapy

Legal Events

Date Code Title Description
FG Grant or registration